ArticleBMJ open2026
Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study: protocol for an international multicentre prospective cohort.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06347237 (PsA Digital Phenotyping and Inflammation Drivers Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PsA Digital Phenotyping and Inflammation Drivers Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChanges in psoriatic arthritis (PsA) disease activity, particularly flares, are unpredictable and can impact patients' quality of life. Digital biomarkers derived from data collected via smart devices provide an opportunity for unobtrusive continuous monitoring of symptoms reflecting disease activity. Besides, our understanding of the mechanisms and triggers behind flares is limited. The primary objectives of the Psoriatic Arthritis Digital Phenotyping and Inflammation Drivers (PDPID) study are: (1) to develop digital biomarker capable of detecting PsA flare using data collected from patient's smartphone and smartwatch, and (2) to develop machine learning models for PsA flare prediction using clinical, biological, environmental and digital data. METHODS AND ANALYSIS: The PDPID study is a 12-month multi-centre prospective cohort study conducted across four countries. Study visits are scheduled at baseline (T0), and 3, 6, 9 and 12 months follow-up visits, with additional patient-initiated visits due to flare. At inclusion, patients have a study app installed on their smartphone and receive a smartwatch. Flare information is collected using physician- and patient-reported flare questionnaires administered at each visit, and via the flare button in the app that patients can activate. The study collects clinical data (physical measurements, questionnaires), biological markers (salivary DNA, gut microbiome, hair cortisol, C-reactive protein) and environmental exposure data (weather and air pollution). The app includes in-app questionnaires, active photo and video tests and passively captures digital data from the smartphone and smartwatch sensors. ETHICS AND DISSEMINATION: Ethical approval has been granted from each of the participating countries (Erasmus MC, the Netherlands: MEC-2023-0470; HRA and Health and Care Research Wales, UK: 332916 NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Ethical Committee (CEFCM), Portugal (124/2023/CEFCM); MREC Hipokrateion Hospital Thessaloniki, Greece: 5549/31.01.24). Findings of this study will be disseminated through reports to the funding body, the project website, newsletters, social media, national and international conferences and symposiums, and scientific publications. TRIAL REGISTRATION NUMBER: NCT06347237.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.